Financials
Financial year 2025
ESPharma from Anderlecht, company number BE1014613268, closed financial year 2025 with a result of € 40,204 after tax. For that financial year ESPharma recorded a gross margin of € 51,161 and equity of € 55,529. Compared with financial year 2024, the result moved from € 15,491 to € 40,204. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 29, 2026.
€ 55,529
▲ 244% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 40,204
▲ 160% vs 2024
Profit after tax over the fiscal year.
€ 26,514
▲ 6% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 833 paid out
2 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 1,122
▲ € 962 vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 17,333
▲ 86% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|
| Gross margin | € 20,543 | € 51,161 | ▲ 149% |
| Profit after taxes | € 15,491 | € 40,204 | ▲ 160% |
| Equity | € 16,158 | € 55,529 | ▲ 244% |
| Total debts | € 11,155 | € 19,296 | ▲ 73% |
| Cash | € 25,044 | € 26,514 | ▲ 6% |
| Retained profit | € 14,658 | € 54,029 | ▲ 269% |
| Dividend | € 833 | € 833 | |
| Balance sheet total | € 27,314 | € 74,825 | ▲ 174% |
By gross margin, ESPharma ranks 40th of 52 companies with main activity “Detailhandel in farmaceutische producten” in Anderlecht that publish figures (fiscal year 2025).
Key figures of ESPharma, fiscal years 2024 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
Ask about ESPharma the way you would ask their accountant.
Answers from the filed annual accounts, the Belgian Official Gazette and the CBE register.
Connect ChatGPT or Claude for free- ChatGPT
- Claude
Free account, no payment card. Key figures unlimited, the annual accounts and deeds of 10 companies a month. Need more? Get in touch, we are looking for our first pilot users.
What happened to ESPharma?
What happened at ESPharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New establishment in La Roche-en-Ardenne. KBO
- New annual accounts for financial year 2025: profit of € 40,204 (▲ 160% vs 2024). Source: NBB ↗
- Incorporation, published in the Gazette. Source: Staatsblad ↗
- New establishment in Anderlecht. KBO
- Emilie Sabine Spilborghs became a director. NBB
In short
From € 15,491 profit in 2024 to € 40,204 profit in 2025.
Paid € 15,192 in corporate taxes since 2024.
Best year ever: 2025, with € 40,204 profit.
Paid out € 1,666 in dividends to the owners in total.
Management
Behind ESPharma is Emilie Sabine Spilborghs.
Directors
According to the 2025 annual accounts
Emilie Sabine Spilborghs
Director
since 2024
Establishments
Establishment units
Physical locations of this company
Henri Caronstraat 7/0001
1070 Anderlecht
Rue de Cielle 4 box A 2 LA0003
6980 La Roche-en-Ardenne
Active since 1 October 2026
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Similar companies in Anderlecht
Same main activity (Detailhandel in farmaceutische producten), 57 active companies in Anderlecht, largest first.
€ 580.8 million revenue · 2025
€ 152.2 million revenue · 2025
€ 16.9 million revenue · 2025
€ 1.9 million gross margin · 2024
€ 914,402 gross margin · 2025
€ 870,107 gross margin · 2026
Shareholders according to the Official Gazette deeds
Who contributed at incorporation and at capital increases, with the deed as source. Later share transfers are not published in the Gazette.
Incorporation
Source: Deed ↗- SPILBORGHS Emilie Sabine Philippine(oprichter) 100%
Details
- Company number
- 1014.613.268
- VAT number
- BE 1014.613.268
- Registered office
- Henri Caronstraat 7/0001, 1070 Anderlecht
- Names & denominations
- ESPharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 3 October 2024
- Peppol
- Active · Active since 15 Dec 2025
- Contact
- [email protected]
- Activities · NACE
Detailhandel in farmaceutische producten